Pfizer official touted “significant opportunity” for the pharmaceutical giant to increase the price of its COVID-19 vaccine once the spread of the virus shifts from pandemic to endemic, but Pfizer says it’s “too early to speculate.”Speaking to investors during the virtual Barclays Global Healthcare Conference last week, Frank A.
D’Amelio, Pfizer’s CFO and executive vice-president of global supply, said the pharmaceutical giant was selling its vaccines at “pandemic pricing,” indicating that could change once most of the world had received its first dose.“So the one price that we published is the price with the U.S.
of $19.50 per dose. Obviously, that’s not a normal price like we typically get for a vaccine, $150, $175 per dose,” he said.